Across 55 European myelodysplastic syndrome Phase 2 & 3 trials, 21 trials used at least one CRO or CRO-like operational partner, equal to 38.2% of the cohort. CRO use was higher in Phase 3 than Phase 2, at 9/18 trials (50.0%) versus 14/40 trials (35.0%), and was most concentrated in multicountry studies: 10/15 trials with 5+ countries used CRO support (66.7%).
Among the 21 CRO-supported trials, PPD / Thermo Fisher appeared in 7 trials (33.3%). ICON Clinical Research appeared in 5 trials (23.8%), while IQVIA, Endpoint Clinical and Almac Clinical Services each appeared in 4 trials (19.0% each). Counts are trial mentions; one trial can list more than one CRO or specialist CRO-like partner.
The active CRO set is split between full-service CROs and specialist operational vendors. PPD / Thermo Fisher is the clearest Phase 3-heavy provider, while ICON, IQVIA, Endpoint and Almac appear across operational, data, IRT, laboratory and supply-chain roles.
Only 5/26 single-country trials used CRO support (19.2%), compared with 6/14 trials with 2–4 countries (42.9%) and 10/15 trials with 5+ countries (66.7%). Participant load also mattered: CRO use was 5/25 trials (20.0%) for ≤50 participants, versus 8/15 trials (53.3%) in both the 51–150 and 151+ participant groups.
| Capacity signal | CRO use | Rate |
|---|---|---|
| 5+ countries | 10 / 15 | 66.7% |
| 151+ participants | 8 / 15 | 53.3% |
| 51–150 participants | 8 / 15 | 53.3% |
| 2–4 countries | 6 / 14 | 42.9% |
| 16+ sites | 11 / 26 | 42.3% |
| Single country | 5 / 26 | 19.2% |
The strongest operational trigger for CRO use is not simply site count; it is cross-country coordination. Once a trial crosses into 5+ CTIS country submissions, CRO use becomes the majority model.
CRO use was highest in relapsed/refractory MDS, where 3/3 trials used CRO support (100.0%). MDS/chronic myelomonocytic leukemia overlap followed at 3/5 trials (60.0%), then higher-risk or excess-blast MDS at 7/16 trials (43.8%). Disease categories are not mutually exclusive because several CTIS disease fields combine MDS with AML, CMML, anemia or transfusion-burden labels.
The highest CRO-need disease segments are clinically and operationally harder to execute: relapsed/refractory disease, higher-risk disease and MDS/CMML overlap require tighter eligibility management, specialized hematology sites and more centralized testing.
The most common outsourced function cluster was central lab, biomarker and sample analytics, appearing in 20/55 trials (36.4%). Data systems, eCOA, EDC and IRT appeared in 18/55 trials (32.7%), matching IMP supply, Qualified Person release and logistics at 18/55 trials (32.7%). CTIS/EU submission and country start-up support appeared in 11/55 trials (20.0%).
| Central lab, biomarker and sample analytics | 20 / 55 | 36.4% |
| Data systems, eCOA, EDC and IRT | 18 / 55 | 32.7% |
| IMP supply, QP release and logistics | 18 / 55 | 32.7% |
| Recruitment, patient support and travel | 13 / 55 | 23.6% |
| Regulatory, CTIS and country start-up | 11 / 55 | 20.0% |
| Pharmacovigilance and safety reporting | 10 / 55 | 18.2% |
| Clinical operations and monitoring | 8 / 55 | 14.5% |
MDS outsourcing is not limited to generic monitoring. The most repeated external needs are hematology-specific: central laboratory testing, biomarker/sample handling, IRT/eCOA/data platforms, IMP supply and country start-up for CTIS/EU submission execution.
The MDS Phase 2 & 3 cohort generated 184 CTIS country activations across 21 European countries, representing 1,051 listed sites and 4,963 country-level participant allocations. France led site and participant footprint with 265 sites and 1,196 participants across 25 trial-country activations, followed by Germany with 191 sites and 756 participants across 25 activations.
| Country | Sites | Participants | CRO activations |
|---|---|---|---|
| France | 265 | 1,196 | 12 |
| Germany | 191 | 756 | 13 |
| Spain | 163 | 734 | 15 |
| Italy | 147 | 922 | 13 |
| Poland | 48 | 207 | 10 |
For CTIS/EU submission planning, the practical CRO opportunity is concentrated in four high-burden countries: France, Germany, Spain and Italy. These markets combine high site count, high participant allocation and repeated CRO-supported trial-country activations.
Across 176 country-level CTIS Part II timelines with processing-day values, the median processing time was 78.5 days. CRO-supported trial-country activations had a median of 242.0 days across 106 timelines, compared with 39.5 days across 70 timelines for non-CRO trial-country activations.
CRO-supported trials are associated with more complex CTIS/EU submission operations: more countries, more sites and longer country-level timelines. This makes regulatory start-up, country coordination and Part II document management a clear commercial entry point for CROs.
Pharmaceutical-company sponsors used CRO support in 19/28 trials (67.9%), compared with 2/10 hospital-sponsored trials (20.0%) and 0/9 patient-organization-sponsored trials (0.0%). By modality, small molecules represented the largest absolute CRO market with 15/40 trials using CROs (37.5%), while peptide/protein/enzyme trials used CROs in 5/11 trials (45.5%).
The strongest commercial target is not investigator-led MDS research; it is sponsor-led development where pharmaceutical companies need scalable EU trial execution, CTIS country start-up, specialist laboratories, IRT/eCOA platforms and supply-chain partners.
MDS means myelodysplastic syndrome. CRO means contract research organization. CTIS means Clinical Trials Information System. IMP means investigational medicinal product. eCOA means electronic clinical outcome assessment. EDC means electronic data capture. IRT means interactive response technology. QP means Qualified Person. CMML means chronic myelomonocytic leukemia. AML means acute myeloid leukemia.